Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A.

Blood. 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. Epub 2012 Jan 13.

2.

Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.

Ellis JT, Peterson P, Geller SA, Rappaport H.

Semin Hematol. 1986 Apr;23(2):144-55.

PMID:
3704666
3.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
4.

New and old prognostic factors in polycythemia vera.

Passamonti F.

Curr Hematol Malig Rep. 2009 Jan;4(1):19-24. doi: 10.1007/s11899-009-0003-8.

PMID:
20425434
5.

Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.

Tiziana Storlazzi C, Pieri L, Paoli C, Daniele G, Lasho T, Tefferi A, Vannucchi AM.

Am J Hematol. 2014 Apr;89(4):438-42. doi: 10.1002/ajh.23659.

6.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
7.

The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.

Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B.

Eur J Haematol. 2011 Feb;86(2):148-55. doi: 10.1111/j.1600-0609.2010.01548.x. Epub 2010 Dec 22.

PMID:
21059102
8.

Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.

Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, Engström-Laurent A.

Med Oncol. 2007;24(1):63-70.

PMID:
17673813
9.

Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.

Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, Noguchi M, Koike M, Sato E, Ohsaka A, Komatsu N.

Int J Hematol. 2015 Feb;101(2):148-53. doi: 10.1007/s12185-014-1721-9. Epub 2014 Dec 19.

PMID:
25522845
10.

The bone marrow in polycythemia vera.

Ellis JT, Peterson P.

Pathol Annu. 1979;14 Pt 1:383-403. Review.

PMID:
390480
11.

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M.

Leukemia. 2010 Sep;24(9):1574-9. doi: 10.1038/leu.2010.148. Epub 2010 Jul 15.

PMID:
20631743
12.

The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.

Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC.

APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17.

PMID:
21749449
13.

High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.

Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP.

Mod Pathol. 2014 Nov;27(11):1447-54. doi: 10.1038/modpathol.2014.69. Epub 2014 Apr 25.

14.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
15.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.

16.
17.

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.

Int J Hematol. 2007 Aug;86(2):130-6.

PMID:
17875526
18.

Contribution of bone marrow biopsy in the diagnosis and prognosis of polycythemia vera.

de Mascarel A.

Nouv Rev Fr Hematol. 1994 Apr;36(2):165-6.

PMID:
8036134
19.

The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia.

Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ.

Cancer. 1987 May 15;59(10):1739-43.

20.

Transformation of polycythemia vera to chronic myelogenous leukemia.

Mirza I, Frantz C, Clarke G, Voth AJ, Turner R.

Arch Pathol Lab Med. 2007 Nov;131(11):1719-24.

PMID:
17979493
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk